AnGes, Inc. (TYO:4563)

Market Cap	11.17B -63.3%
Revenue (ttm)	962.00M +35.5%
Net Income	-3.87B
EPS	-9.96
Shares Out	398.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	915,300
Open	29.00
Previous Close	29.00
Day's Range	28.00 - 29.00
52-Week Range	28.00 - 93.00
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 56
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4563

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 26, 2026

Data Sources Report a data error